Mild Cognitive Impairment Pipeline Assessment by Drug Target, MoA, RoA and More

PUNE, India, October 9, 2015 /PRNewswire/ --

Market research titled Mild Cognitive Impairment - Pipeline Review, H2 2015 is a report providing data and information that helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on Mild Cognitive Impairment pipeline spread across 93 pages, analyzing 11 companies, 21 drug profiles and supported with 28 tables and 15 figures is now available at http://www.lifescienceindustryresearch.com/mild-cognitive-impairment-pipeline-review-h2-2015.html .

This report provides comprehensive information on the therapeutic development for Mild cognitive impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild cognitive impairment and special features on late-stage and discontinued projects. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies mentioned in this Mild Cognitive Impairment pipeline H2 2015 review report include Actinogen Limited, Avraham Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, CereSpir Incorporated, D-Pharm Ltd., Eisai Co., Ltd., Eli Lilly and Company, Octapharma AG, Sage Therapeutics, Sanofi and Suven Life Sciences Ltd. Drug profiles discussed in this report are BAN-2401, BCA-909, CSP-1103, DAOI-B, DP-NDD, immune globulin (human), insulin (human), ladostigil tartrate, levetiracetam, LY-3002813, SAGE-547, SAR-228810, Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders, SUVN-501, SUVN-502, SUVN-507, SUVN-512, SUVN-976, SUVND-4010, tropisetron hydrochloride and UE-2343. Order a copy of Mild Cognitive Impairment - Pipeline Review, H2 2015 market research report at http://www.lifescienceindustryresearch.com/purchase?rname=58502 .

The report provides a snapshot of the global therapeutic landscape of Mild cognitive impairment and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Mild cognitive impairment and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Mild cognitive impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Mild cognitive impairment pipeline on the basis of target, MoA, route of administration and molecule type, latest news and deals relating related to pipeline products.

Another newly published market research titled Global Alzheimer's Drugs Industry Report 2015 is a report providing basic overview of the industry including definitions, classifications, applications and industry chain structure. The Alzheimer's Drugs market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.The Alzheimer's Drugs industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered with the help of this Global Alzheimer's Drugs Industry Report 2015 of 210 pages available at http://www.lifescienceindustryresearch.com/global-alzheimers-drugs-industry-report-2015.html .

Explore more reports on Pharmaceuticals market at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .

About Us:   

LifeScienceIndustryResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:  

G+ / Google Plus: https://plus.google.com/112612135957880308475/about

Twitter: https://twitter.com/LifeSciReports

RSS / Feeds: http://www.lifescienceindustryresearch.com/feed/

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@lifescienceindustryresearch.com